JP2021530478A - ＮａＶ１．８を阻害するためのピリジンカルボキシアミド化合物 - Google Patents

ＮａＶ１．８を阻害するためのピリジンカルボキシアミド化合物 Download PDF

Info

Publication number
JP2021530478A
JP2021530478A JP2021500411A JP2021500411A JP2021530478A JP 2021530478 A JP2021530478 A JP 2021530478A JP 2021500411 A JP2021500411 A JP 2021500411A JP 2021500411 A JP2021500411 A JP 2021500411A JP 2021530478 A JP2021530478 A JP 2021530478A
Authority
JP
Japan
Prior art keywords
trifluoromethyl
carboxamide
pyridine
group
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021500411A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021530478A5 (enExample
Inventor
ポスラスニー マイケル
アーンスト グレン
バロウ ジェームズ
フアン イーファン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lieber Institute Inc
Original Assignee
Lieber Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lieber Institute Inc filed Critical Lieber Institute Inc
Publication of JP2021530478A publication Critical patent/JP2021530478A/ja
Publication of JP2021530478A5 publication Critical patent/JP2021530478A5/ja
Priority to JP2024111875A priority Critical patent/JP2024153683A/ja
Priority to JP2025150845A priority patent/JP2026009899A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A61K31/51—Thiamines, e.g. vitamin B1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/56—Amides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/84—Nitriles
    • C07D213/85—Nitriles in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2021500411A 2018-07-09 2019-07-09 ＮａＶ１．８を阻害するためのピリジンカルボキシアミド化合物 Pending JP2021530478A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2024111875A JP2024153683A (ja) 2018-07-09 2024-07-11 ＮａＶ１．８を阻害するピリジンカルボキサミド化合物
JP2025150845A JP2026009899A (ja) 2018-07-09 2025-09-11 ＮａＶ１．８を阻害するピリジンカルボキサミド化合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862695571P 2018-07-09 2018-07-09
US62/695,571 2018-07-09
PCT/US2019/041029 WO2020014246A1 (en) 2018-07-09 2019-07-09 Pyridine carboxamide compounds for inhibiting nav1.8

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024111875A Division JP2024153683A (ja) 2018-07-09 2024-07-11 ＮａＶ１．８を阻害するピリジンカルボキサミド化合物

Publications (2)

Publication Number Publication Date
JP2021530478A true JP2021530478A (ja) 2021-11-11
JP2021530478A5 JP2021530478A5 (enExample) 2022-04-12

Family

ID=69141639

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2021500411A Pending JP2021530478A (ja) 2018-07-09 2019-07-09 ＮａＶ１．８を阻害するためのピリジンカルボキシアミド化合物
JP2024111875A Pending JP2024153683A (ja) 2018-07-09 2024-07-11 ＮａＶ１．８を阻害するピリジンカルボキサミド化合物
JP2025150845A Pending JP2026009899A (ja) 2018-07-09 2025-09-11 ＮａＶ１．８を阻害するピリジンカルボキサミド化合物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2024111875A Pending JP2024153683A (ja) 2018-07-09 2024-07-11 ＮａＶ１．８を阻害するピリジンカルボキサミド化合物
JP2025150845A Pending JP2026009899A (ja) 2018-07-09 2025-09-11 ＮａＶ１．８を阻害するピリジンカルボキサミド化合物

Country Status (9)

Country Link
US (2) US12234221B2 (enExample)
EP (1) EP3820866A4 (enExample)
JP (3) JP2021530478A (enExample)
KR (1) KR20210019581A (enExample)
CN (1) CN112689633B (enExample)
AU (2) AU2019301628C1 (enExample)
CA (1) CA3105657A1 (enExample)
SG (1) SG11202100130QA (enExample)
WO (1) WO2020014246A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024153683A (ja) * 2018-07-09 2024-10-29 リーバー インスティチュート インコーポレイテッド ＮａＶ１．８を阻害するピリジンカルボキサミド化合物

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020176763A1 (en) 2019-02-27 2020-09-03 Vertex Pharmaceuticals Incorporated Dosage form comprising prodrug of na 1.8 sodium channel inhibitor
WO2020219867A1 (en) 2019-04-25 2020-10-29 Vertex Pharmaceuticals Incorporated Pyridone amide co-crystal compositions for the treatment of pain
CN112390745B (zh) * 2019-08-19 2022-10-21 江苏恒瑞医药股份有限公司 吡啶烟酰胺类衍生物、其制备方法及其在医药上的应用
BR112022004495A8 (pt) * 2019-09-12 2023-04-18 Jiangxi Jemincare Group Co Ltd Compostos oxinitreto de piridina, composição farmacêutica compreendendo os mesmos e usos dos mesmos
BR112022010924A2 (pt) 2019-12-06 2022-09-06 Vertex Pharma Tetra-hidrofuranos substituídos como moduladores de canais de sódio
CN114591293A (zh) * 2020-12-07 2022-06-07 成都康弘药业集团股份有限公司 作为Nav1.8抑制剂的并环化合物及其用途
MX2023010638A (es) 2021-03-11 2023-11-28 Latigo Biotherapeutics Inc Compuestos de piridina y piridazina metil-sustituidos, derivados de los mismos y métodos de su uso.
CN116829539B (zh) * 2021-03-11 2025-11-25 上海济煜医药科技股份有限公司 吡啶氮氧化合物晶型及其应用
US20240400544A1 (en) 2021-06-04 2024-12-05 Vertex Pharmaceuticals Incorporated N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamide analogs as modulators of sodium channels
CA3221938A1 (en) 2021-06-04 2022-12-08 Vertex Pharmaceuticals Incorporated Substituted tetrahydrofuran analogs as modulators of sodium channels
WO2022256842A1 (en) 2021-06-04 2022-12-08 Vertex Pharmaceuticals Incorporated Hydroxy and (halo)alkoxy substituted tetrahydrofurans as modulators of sodium channels
AU2022283934A1 (en) 2021-06-04 2023-11-30 Vertex Pharmaceuticals Incorporated Substituted tetrahydrofuran-2-carboxamides as modulators of sodium channels
HRP20260068T1 (hr) 2021-06-04 2026-02-27 Vertex Pharmaceuticals Incorporated Čvrsti farmaceutski oblici i režimi doziranja koji obuhvaćaju (2r,3s,4s,5r)-4-[[3-(3,4-difluor-2-metoksifenil)-4,5-dimetil-5-(trifluormetil)tetrahidrofuran-2-karbonil]amino]piridin-2-karboksamid
SMT202500481T1 (it) 2021-06-04 2026-01-12 Vertex Pharma N-(idrossialchil(etero)aril)tetraidrofuran carbossammidi come modulatori di canali del sodio
US20250154109A1 (en) * 2022-02-04 2025-05-15 Latigo Biotherapeutics, Inc Sodium channel blocking compounds, derivatives thereof, and methods of their use
CN116655497B (zh) * 2022-02-25 2025-06-03 中国科学院上海药物研究所 脒类衍生化合物及其制备方法和用途
CN116891432A (zh) * 2022-04-02 2023-10-17 武汉人福创新药物研发中心有限公司 Nav1.8抑制剂及其用途
CA3256248A1 (en) 2022-04-22 2023-10-26 Vertex Pharmaceuticals Incorporated HETEROARYL COMPOUNDS FOR PAIN RELIEF
US20230382910A1 (en) 2022-04-22 2023-11-30 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
WO2023205463A1 (en) 2022-04-22 2023-10-26 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
CA3257285A1 (en) 2022-04-22 2023-10-26 Vertex Pharmaceuticals Incorporated HETEROARYL COMPOUNDS FOR PAIN RELIEF
JP2025516005A (ja) 2022-04-25 2025-05-23 サイトワン セラピューティクス インコーポレイテッド 疼痛の処置のためのｎａｖ１．８の二環式複素環アミド阻害剤
TW202400560A (zh) * 2022-04-28 2024-01-01 南韓商愛思開生物製藥股份有限公司 Ｎ－氧化物化合物及其用途
WO2024123815A1 (en) 2022-12-06 2024-06-13 Vertex Pharmaceuticals Incorporated Process for the synthesis of substituted tetrahydrofuran modulators of sodium channels
WO2025090511A1 (en) 2023-10-23 2025-05-01 Vertex Pharmaceuticals Incorporated Methods of preparing modulators of sodium channels and solid forms of the same for treating pain
WO2025090480A1 (en) 2023-10-23 2025-05-01 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
WO2025090465A1 (en) 2023-10-23 2025-05-01 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
WO2025090516A1 (en) 2023-10-23 2025-05-01 Vertex Pharmaceuticals Incorporated Methods of preparing compounds for treating pain and solid forms thereof
US20250186419A1 (en) 2023-12-07 2025-06-12 Vertex Pharmaceuticals Incorporated Dosing regimens for treating pain
WO2025160286A1 (en) 2024-01-24 2025-07-31 Siteone Therapeutics, Inc. 2-aryl cycloalkyl and heterocycloalkyl inhibitors of nav1.8 for the treatment of pain
US20260001877A1 (en) 2024-06-28 2026-01-01 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
WO2026013449A2 (en) 2024-07-11 2026-01-15 Sea4Us - Biotecnologia E Recursos Marinhos, Sa Oxazolidone-derived compounds and their use in the treatment of chronic and acute pain
WO2026030525A1 (en) 2024-07-31 2026-02-05 Vertex Pharmaceuticals Incorporated Zilvetrigine dosage forms and dosing regimens for treating pain

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57118568A (en) * 1980-11-21 1982-07-23 May & Baker Ltd Nicotine amide derivative and manufacture, herbicidal composition and method of controlling weed growth
WO2001023356A1 (de) * 1999-09-30 2001-04-05 Bayer Aktiengesellschaft Substituierte n-phenyl-phenoxynicotinsäure-(thio)amide und ihre verwendung als herbizide
JP2004238361A (ja) * 2003-02-07 2004-08-26 Tosoh Corp ピリミジン−５−カルボキサミド誘導体、その中間体及びそれらの製造方法
JP2005522450A (ja) * 2002-02-11 2005-07-28 ファイザー・インク Ｐｄｅ４阻害剤として有用なニコチンアミド誘導体
JP2007509924A (ja) * 2003-10-31 2007-04-19 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー ホスホイノシチド−３−キナーゼ（ｐｉ３ｋ）阻害剤としてのピリミジン
JP2011500598A (ja) * 2007-10-11 2011-01-06 バーテックス ファーマシューティカルズ インコーポレイテッド 電位開口型ナトリウムチャネルの阻害剤として有用なヘテロアリールアミド
CN102850321A (zh) * 2011-06-28 2013-01-02 中国科学院上海药物研究所 芳香氧基嘧啶甲酰胺或芳香氧基吡啶甲酰胺类化合物及其制备方法、药物组合物和用途
JP2024153683A (ja) * 2018-07-09 2024-10-29 リーバー インスティチュート インコーポレイテッド ＮａＶ１．８を阻害するピリジンカルボキサミド化合物

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2114654T3 (es) 1993-06-08 1998-06-01 Vertex Pharma Piridazinas como inhibidores de la enzima de conversion de la interleuquina-1beta.
US7504396B2 (en) * 2003-06-24 2009-03-17 Amgen Inc. Substituted heterocyclic compounds and methods of use
EP1673357A2 (en) 2003-08-08 2006-06-28 Vertex Pharmaceuticals Incorporated Heteroarylaminosulfonylphenyl derivatives for use as sodium or calcium channel blockers in the treatment of pain
CN1863785A (zh) * 2003-08-08 2006-11-15 沃泰克斯药物股份有限公司 在疼痛的治疗中用作钠或钙通道阻断剂的杂芳基氨基磺酰基苯基衍生物
AU2004285053B2 (en) 2003-10-28 2010-10-21 Vertex Pharmaceuticals, Incorporated Benzimidazoles useful as modulators of ion channels
CA2608599A1 (en) 2005-05-16 2006-11-23 Vertex Pharmaceuticals Incorporated Bicyclic derivatives as modulators of ion channels
MX2007015726A (es) 2005-06-09 2008-03-04 Vertex Pharma Derivados de indano como moduladores de canales ionicos.
MX2008003337A (es) 2005-09-09 2008-09-26 Vertex Pharma Derivados biciclicos como modulares de canales ionicos regulados por voltaje.
EP1934191B1 (en) 2005-10-12 2012-03-28 Vertex Pharmaceuticals, Inc. Biphenyl derivatives as modulators of voltage gated ion channels
WO2008060789A2 (en) 2006-10-12 2008-05-22 Xenon Pharmaceuticals Inc. Use of spiro-oxindole compounds as therapeutic agents
KR20100075631A (ko) * 2007-10-11 2010-07-02 버텍스 파마슈티칼스 인코포레이티드 전압­개폐 나트륨 채널의 억제제로서 유용한 아릴 아미드
WO2009049181A1 (en) 2007-10-11 2009-04-16 Vertex Pharmaceuticals Incorporated Amides useful as inhibitors of voltage-gated sodium channels
BRPI0919648A2 (pt) * 2008-10-29 2015-12-08 Hoffmann La Roche novos derivados de fenil amida ou piridil amida e seu uso como agonistas de gpbar1
AU2009308982A1 (en) 2008-10-30 2010-05-06 Merck Sharp & Dohme Corp. Pyridazine carboxamide orexin receptor antagonists
AR077252A1 (es) 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
WO2011026240A1 (en) 2009-09-04 2011-03-10 Zalicus Pharmaceuticals Ltd. Oxopiperazine derivatives for the treatment of pain and epilepsy
US8598164B2 (en) 2010-05-06 2013-12-03 Vertex Pharmaceuticals Incorporated Heterocyclic chromene-spirocyclic piperidine amides as modulators of ion channels
KR101923367B1 (ko) 2011-02-02 2018-12-04 버텍스 파마슈티칼스 인코포레이티드 이온 채널의 조절제로서의 피롤로피라진―스피로사이클릭 피페리딘 아미드
MX2013009393A (es) 2011-02-18 2013-08-29 Vertex Pharma Piperidinamidas cromano-espirociclicas como moduladores de canales de iones.
CA2828456C (en) 2011-03-03 2021-05-04 Zalicus Pharmaceuticals Ltd. N-benzl-amino-carboxamide inhibitors of the sodium channel
CN103517910B (zh) 2011-03-14 2016-12-14 沃泰克斯药物股份有限公司 作为离子通道调节剂的吗啉-螺环哌啶酰胺
NZ627259A (en) 2012-01-16 2016-12-23 Vertex Pharma Pyran-spirocyclic piperidine amides as modulators of ion channels
RU2683788C2 (ru) 2013-01-31 2019-04-02 Вертекс Фармасьютикалз Инкорпорейтед Амиды хинолина и хиназолина, полезные в качестве модуляторов натриевых каналов
US9120786B2 (en) 2013-03-04 2015-09-01 Purdue Pharma, L.P. Triazine carboxamides as sodium channel blockers
CA2939549C (en) 2013-03-15 2020-08-18 Purdue Pharma L.P. Carboxamide derivatives and use thereof
UA119147C2 (uk) * 2013-07-19 2019-05-10 Вертекс Фармасьютікалз Інкорпорейтед Сульфонаміди як модулятори натрієвих каналів
CA2931550C (en) 2013-12-13 2023-09-26 Vertex Pharmaceuticals Incorporated Prodrugs of pyridone amides useful as modulators of sodium channels
US9452986B2 (en) 2014-02-06 2016-09-27 Abbvie Inc. 6-heteroaryloxy- or 6-aryloxy-quinoline-2-carboxamides and method of use
CN106715418A (zh) 2014-07-07 2017-05-24 基因泰克公司 治疗化合物及其使用方法
EP3580220B1 (en) 2017-02-13 2021-11-17 Bristol-Myers Squibb Company Aminotriazolopyridines as kinase inhibitors
AU2018300150A1 (en) 2017-07-11 2020-01-30 Vertex Pharmaceuticals Incorporated Carboxamides as modulators of sodium channels

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57118568A (en) * 1980-11-21 1982-07-23 May & Baker Ltd Nicotine amide derivative and manufacture, herbicidal composition and method of controlling weed growth
WO2001023356A1 (de) * 1999-09-30 2001-04-05 Bayer Aktiengesellschaft Substituierte n-phenyl-phenoxynicotinsäure-(thio)amide und ihre verwendung als herbizide
JP2005522450A (ja) * 2002-02-11 2005-07-28 ファイザー・インク Ｐｄｅ４阻害剤として有用なニコチンアミド誘導体
JP2004238361A (ja) * 2003-02-07 2004-08-26 Tosoh Corp ピリミジン−５−カルボキサミド誘導体、その中間体及びそれらの製造方法
JP2007509924A (ja) * 2003-10-31 2007-04-19 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー ホスホイノシチド−３−キナーゼ（ｐｉ３ｋ）阻害剤としてのピリミジン
JP2011500598A (ja) * 2007-10-11 2011-01-06 バーテックス ファーマシューティカルズ インコーポレイテッド 電位開口型ナトリウムチャネルの阻害剤として有用なヘテロアリールアミド
CN102850321A (zh) * 2011-06-28 2013-01-02 中国科学院上海药物研究所 芳香氧基嘧啶甲酰胺或芳香氧基吡啶甲酰胺类化合物及其制备方法、药物组合物和用途
JP2024153683A (ja) * 2018-07-09 2024-10-29 リーバー インスティチュート インコーポレイテッド ＮａＶ１．８を阻害するピリジンカルボキサミド化合物

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHEUNG, P. K. ET AL.: "A Parallel Synthesis Approach to the Identification of Novel Diheteroarylamide-Based Compounds Block", JOURNAL OF MEDICINAL CHEMISTRY, vol. 59, no. 5, JPN6023026880, 2016, pages 1869 - 1879, XP055534189, ISSN: 0005280614, DOI: 10.1021/acs.jmedchem.5b01357 *
CRAMP, M. C. ET AL.: "Design and synthesis of N-(2,4-difluorophenyl)-2-(3-trifluoromethylphenoxy)-3-pyridinecarboxamide (d", PESTICIDE SCIENCE, vol. 18, no. 1, JPN6023026878, 1987, pages 15 - 28, ISSN: 0005280612 *
O'HARA, F. ET AL.: "Radical-Based Regioselective C-H Functionalization of Electron-DeficientHeteroarenes: Scope, Tunabil", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 135, no. 32, JPN6023026879, 2013, pages 12122 - 12134, ISSN: 0005280613 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024153683A (ja) * 2018-07-09 2024-10-29 リーバー インスティチュート インコーポレイテッド ＮａＶ１．８を阻害するピリジンカルボキサミド化合物

Also Published As

Publication number Publication date
EP3820866A4 (en) 2022-04-06
AU2025200580A1 (en) 2025-02-20
US20220227732A1 (en) 2022-07-21
SG11202100130QA (en) 2021-02-25
AU2019301628B2 (en) 2024-10-31
CN112689633A (zh) 2021-04-20
AU2019301628A1 (en) 2021-01-28
JP2026009899A (ja) 2026-01-21
JP2024153683A (ja) 2024-10-29
CA3105657A1 (en) 2020-01-16
US12234221B2 (en) 2025-02-25
EP3820866A1 (en) 2021-05-19
US20260001861A1 (en) 2026-01-01
CN112689633B (zh) 2025-01-24
AU2019301628C1 (en) 2025-02-06
KR20210019581A (ko) 2021-02-22
WO2020014246A1 (en) 2020-01-16

Similar Documents

Publication Publication Date Title
JP2021530478A (ja) ＮａＶ１．８を阻害するためのピリジンカルボキシアミド化合物
EP3820860B1 (en) Pyridazine compounds for inhibiting nav1.8
EP3625214B1 (en) Deuterated pyridone amides and prodrugs thereof as modulators of sodium channels
US12441703B2 (en) Carboxamides as modulators of sodium channels
JP2021530478A5 (enExample)
ES2654393T3 (es) Sulfonamidas como moduladores de los canales de sodio
EP4714435A2 (en) Solid dosage forms and dosing regimens comprising (2r,3s,4s,5r)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl) tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide
RS56015B1 (sr) Piridon amidi kao modulatori natrijumovih kanala
BR112015017997B1 (pt) Amidas de quinolina e quinoxalina como moduladores de canais de sódio, seus usos, e composição farmacêutica
HK40048208A (en) Pyridazine compounds for inhibiting nav1.8
HK40048208B (en) Pyridazine compounds for inhibiting nav1.8
HK40024517A (en) Deuterated pyridone amides and prodrugs thereof as modulators of sodium channels
HK40024517B (en) Deuterated pyridone amides and prodrugs thereof as modulators of sodium channels
EA041031B1 (ru) Дейтерированные пиридонамиды и их пролекарства в качестве модуляторов натриевых каналов
BR112016012811B1 (pt) Pró-fármacos de piridona amidas, suas formas cristalinas,composição que os compreende, processo para preparar a forma b cristalina, e uso

Legal Events

Date Code Title Description
A529 Written submission of copy of amendment under article 34 pct

Free format text: JAPANESE INTERMEDIATE CODE: A529

Effective date: 20210308

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20211108

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211109

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220706

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230620

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230704

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231003

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231201

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240104

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240312

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240711

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20240712

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20240801

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20241108